Current Report Filing (8-k)
13 March 2023 - 9:02PM
Edgar (US Regulatory)
0001130166
false
0001130166
2023-03-10
2023-03-10
0001130166
us-gaap:CommonStockMember
2023-03-10
2023-03-10
0001130166
us-gaap:PreferredStockMember
2023-03-10
2023-03-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange
Act of 1934
Date of Report (Date
of earliest event reported): March 10, 2023
CYCLACEL
PHARMACEUTICALS, INC.
(Exact name of registrant
as specified in its charter)
Delaware |
|
0-50626 |
|
91-1707622 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
200
Connell Drive, Suite 1500
Berkeley
Heights, NJ 07922
(Address of principal
executive offices and zip code)
Registrant’s telephone
number, including area code: (908) 517-7330
(Former Name or Former
Address, if Changed Since Last Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered
|
Common
Stock, par value $0.001 per share |
CYCC |
The Nasdaq Capital Market |
Preferred
Stock, $0.001 par value |
CYCCP |
The Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 7.01 | Regulation FD Disclosure. |
Cyclacel Pharmaceuticals,
Inc. (the "Company") is aware that the Federal Deposit Insurance Corporation has taken control of Silicon Valley Bank
(“SVB”) due to liquidity concerns. The Company does not hold any deposits at SVB or have any other direct investments
at SVB.
The information contained
in this Item 7.01 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information
in this Item 7.01 shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
CYCLACEL PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Paul McBarron |
|
Name: |
Paul McBarron |
|
Title: |
Executive Vice President-Finance, |
|
|
Chief Financial Officer and Chief Operating Officer |
|
Date: March 10, 2023
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From May 2024 to Jun 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Jun 2023 to Jun 2024